levofloxacin
Phase 2/3Completed 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Skin Diseases, Infectious
Conditions
Skin Diseases, Infectious, Cellulitis
Trial Timeline
Jul 1, 1991 → Feb 1, 1993
NCT ID
NCT00257036About levofloxacin
levofloxacin is a phase 2/3 stage product being developed by Johnson & Johnson for Skin Diseases, Infectious. The current trial status is completed. This product is registered under clinical trial identifier NCT00257036. Target conditions include Skin Diseases, Infectious, Cellulitis.
What happened to similar drugs?
16 of 20 similar drugs in Skin Diseases, Infectious were approved
Approved (16) Terminated (4) Active (4)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00002249 | Phase 1 | Completed |
| NCT00210886 | Phase 3 | Completed |
| NCT00645437 | Phase 1 | Completed |
| NCT00236652 | Phase 3 | Completed |
| NCT00044473 | Phase 3 | Completed |
| NCT00236522 | Phase 3 | Completed |
| NCT00034736 | Phase 3 | Completed |
| NCT00236821 | Phase 3 | Completed |
| NCT00236808 | Phase 3 | Completed |
| NCT00249197 | Phase 3 | Completed |
| NCT00269932 | Phase 3 | Completed |
| NCT00249210 | Phase 3 | Completed |
| NCT00258089 | Phase 3 | Completed |
| NCT00258102 | Phase 3 | Completed |
| NCT00257062 | Phase 3 | Completed |
| NCT00257036 | Phase 2/3 | Completed |
| NCT00257049 | Phase 2/3 | Completed |
| NCT00257140 | Phase 2/3 | Completed |
Competing Products
20 competing products in Skin Diseases, Infectious